Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years-Reference-Cited by-同舟云学术

Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years

Published:2008-12 Issue:12 Volume:32 Page:1800-1808
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Candoni Anna,Martinelli Giovanni,Toffoletti Eleonora,Chiarvesio Alexia,Tiribelli Mario,Malagola Michele,Piccaluga Pier Paolo,Michelutti Angela,Simeone Erica,Damiani Daniela,Russo Domenico,Fanin Renato

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference47 articles.

1. Acute myeloid leukemia, review article;Löwenberg;N Engl J Med,1999

2. Acute myeloid leukemia;Stone;Haematology,2004

3. Therapy of acute myeloid leukemia: towards a patient-oriented, risk adapted approach;Mandelli;Haematologica,1998

4. High efficacy of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia;Clavio;Haematologica,1996

5. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose Ara-C and early stem cell transplant. A feasible and effective therapeutic strategy for de novo AML patients;Clavio;J Exp Clin Cancer Res,2002

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful combination chemotherapy involving clofarabine, cyclophosphamide, and etoposide for pediatric relapsed acute myeloid leukemia: A case report;SAGE Open Medical Case Reports;2021-01

2. Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden;Cancers;2020-12-24

3. Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment;Advances in Therapy;2020-04-15

4. Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas;Chimeric Antigen Receptor T-Cell Therapies for Cancer;2020

5. Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML;International Journal of Molecular Sciences;2019-08-29